CLAIMS

1. A method of improving joint function in a hemophilia patient, comprising subcutaneously administering fitusiran to a hemophilia patient in need thereof, optionally wherein the patient is a hemophilia A or B patient with or without inhibitors.

2. The method of claim 1, wherein the administering reduces difficulty in walking or increases mobility.

3. A method of improving a joint symptom in a hemophilia patient, comprising subcutaneously administering fitusiran to a hemophilia patient in need thereof, wherein the joint symptom is selected from joint swelling, painful movement, and joint pain, and optionally wherein the patient is a hemophilia A or B patient with or without inhibitors.

4. A method of improving patient-reported outcome (PRO) in a hemophilia patient, comprising subcutaneously administering fitusiran to a hemophilia patient in need thereof, optionally wherein the patient is a hemophilia A or B patient with or without inhibitors and optionally wherein the PRO is improved in one or more quality-of-life domains.

5. A method of improving quality of life (QoL) in a hemophilia patient, comprising subcutaneously administering fitusiran to a hemophilia patient in need thereof, wherein the QoL is improved in one or more QoL domains and optionally wherein the patient is a hemophilia A or B patient with or without inhibitors.

6. The method of any one of claims 1-5, wherein fitusiran is administered at 40-90 mg per dose.

7. The method of claim 4 or 5, wherein the one or more QoL domains are domains in a QoL questionnaire, optionally wherein the QoL questionnaire is Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL).

8. The method of claim 7, wherein the administering results in a clinically meaningful improvement indicated by a reduction of 7 or more units (optionally 8 or more, 9 or more, or 10 or more units) in one or more of Total Score, Sports and Leisure domain score, and Physical Health domain score of the Questionnaire.

9. The method of any one of claims 1-8, wherein the patient is an adult or adolescent patient twelve years or older with hemophilia A or B with or without inhibitors.

10. The method of any one of claims 1-9, wherein the patient has hemophilia A.

11. The method of claim 10, wherein the patient has been treated with factor VIII or a bypassing agent (BPA).

12. The method of claim 11, wherein the patient is with inhibitors, optionally wherein the level of inhibitors is more than 0.6 BU/mL as determined by Bethesda inhibitor assay.

13. The method of claim 10 or 11, wherein the patient is without inhibitors.

14. The method of any one of claims 1-9, wherein the patient has hemophilia B.

15. The method of claim 14, wherein the patient has been treated with factor IX or a BPA.

16. The method of claim 15, wherein the patient is with inhibitors, optionally wherein the level of inhibitors is more than 0.6 BU/mL as determined by Bethesda inhibitor assay.

17. The method of claim 14 or 15, wherein the patient is without inhibitors.

18. The method of any one of claims 11-13 or 15-17, wherein the BPA is activated prothrombin complex concentrates (aPCC) and/or recombinant activated Factor VII (rFVIIa).

19. The method of any one of claims 1-18, comprising administering to the patient a plurality of doses of fitusiran at 50 mg per dose.

20. The method of any one of claims 1-18, comprising administering to the patient a plurality of doses of fitusiran at 80 mg per dose.

21. The method of any one of claims 1-20, wherein fitusiran is provided at a concentration of 50-200 mg/mL, optionally at a concentration of 100 mg/mL, in a phosphate-buffered saline (pH 7).

22. The method of any one of claims 1-21, wherein fitusiran is administered to the patient once every four weeks or once a month.

23. Fitusiran for use in the method of any one of claims 1-22.

24. An article of manufacture for use in the method of any one of claims 1-22.

25. The article of manufacture for use of claim 24, wherein the article of manufacture is a single-use vial containing 80 mg of fitusiran in 0.8 mL of a phosphate-buffered saline (pH 7).

26. The article of manufacture for use of claim 24, wherein the article of manufacture is a single-use prefilled syringe containing 80 mg of fitusiran in 0.8 mL of a phosphate-buffered saline (pH 7).

27. The article of manufacture for use of claim 24, wherein the article of manufacture is a single-use vial containing 50 mg of fitusiran in 0.5 mL of a phosphate-buffered saline (pH 7).

28. The article of manufacture for use of claim 24, wherein the article of manufacture is a single-use prefilled syringe containing 50 mg of fitusiran in 0.5 mL of a phosphate-buffered saline (pH 7).

29. Use of fitusiran for the manufacture of a medicament to treat hemophilia A or B in the method of any one of claims 1-22.